dolutegravir + elvitegravir + cobicistat

Dolutegravir + elvitegravir + cobicistat is a combination of three antiretroviral agents used in the treatment of HIV-1 infection. Dolutegravir and elvitegravir are both integrase strand transfer inhibitors (INSTIs) that block the integration of viral DNA into the host genome by inhibiting the HIV integrase enzyme[2][4][8]. Cobicistat is a pharmacokinetic enhancer (booster) that inhibits cytochrome P450 3A enzymes to increase plasma concentrations of co-administered drugs such as elvitegravir[3]. This combination targets different steps in the HIV replication cycle and is used as part of highly active antiretroviral therapy (HAART) regimens for adults with HIV-1 infection. These agents do not cure HIV but help suppress viral replication, improve immune function, and reduce disease progression[1][2][3].